Skip to content

Improving Genetic Counseling for BRCA+ Mothers

Parent Communication Study IV: Improving Genetic Counseling for BRCA+ Mothers

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04258280
Acronym
PCS IV
Enrollment
200
Registered
2020-02-06
Start date
2020-07-01
Completion date
2025-12-31
Last updated
2024-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Brief summary

Genetic counseling and testing for hereditary breast cancer may reveal that you, and possibly your blood relatives, are at increased risk for the disease across the lifespan. This includes biological children, both male and female. We do not yet know the best ways to educate mothers who have a risk gene (are BRCA+) about whether, when, and how to share genetic information with their children or manage their thoughts and feelings. The purpose of this study is to help mothers make more informed choices about talking with children about hereditary breast cancer, provide them with age-and gender-appropriate information and emotional support, and improve their psychological well-being.

Interventions

Education includes a workbook, counseling includes peer support.

BEHAVIORALEducation

Education includes a workbook.

Sponsors

Georgetown University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Mothers/primary caregivers to adolescents/young adults ages 13-24 years-old. * Participating in genetic testing for hereditary breast cancer. * Adequately speak/read English.

Exclusion criteria

\- Does not meet inclusion criteria.

Design outcomes

Primary

MeasureTime frameDescription
Communication1- and 6-months post-treatmentParent-child and family communication of hereditary cancer risk.

Countries

United States

Contacts

Primary ContactKenneth Tercyak, PhD
familycom@georgetown.edu202-687-0802

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026